Longer time horizons and therapeutic area expertise make philanthropy venture capital an attractive option for biopharmaceutical companies developing new products. It can also de-risk funding rounds ...

Job rotations provide an opportunity for promising, high-potential employees to grow and learn new parts of the business.

Spinogenix is using small molecule drugs to regenerate synapses in patients with ALS, Alzheimer's disease, schizophrenia, ...

Implementing AI in drug discovery offers significant potential for reducing operating costs, though the extent varies widely.

In the rapidly evolving world of life sciences, companies are constantly seeking ways to optimize their business structures to better navigate the complex landscape of drug development and financing.

This is the second article in a series on “putting people first” as a leader. Click here to read the first article in the series. I've always believed that the true measure of a company's success lies ...

In the rapidly evolving landscape of pharmaceutical development, AI promises to revolutionize the entire drug discovery and development process, impacting target discovery, clinical trial design, site ...

What do Annovis Bio’s buntanetap, Pfizer’s Viagra, and Lilly’s GLP-1 drug Trulicity have in common? They could all end up being used together in combination as a new treatment focused on improving ...

As professionals within the life sciences industry, a new era is upon us, marked by the pursuit of efficiency. In part this has been driven by legislative measures such as the Inflation Reduction Act ...

Dr. Alicia Zhou, Ph.D., the new CEO at the Cancer Research Institute (CRI), aims to bring her experience in academia and the West Coast health tech startup scene to bear on a 70-year-old nonprofit ...